RenovoRx (RNXT) Change in Account Payables (2020 - 2026)
RenovoRx (RNXT) posted Change in Account Payables of $254000.0 for Q1 2026, up 462.86% sequentially from -$70000.0 in Q4 2025, and down 33.33% YoY from $381000.0 in Q1 2025.
RenovoRx (RNXT) Change in Account Payables (2020 - 2026) Analysis & Trends
RenovoRx has reported Change in Account Payables for 7 years, with the latest figure at $254000.0 in Q1 2026.
- Quarterly Change in Account Payables fell 33.33% year-over-year to $254000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $86000.0 (down 85.95% YoY) and the FY2025 annual result came in at $213000.0, up 752.0% from the prior year.
- Change in Account Payables grew to $254000.0 in Q1 2026 per RNXT's latest filing, from -$70000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $381000.0 in Q1 2025 and troughed at -$522000.0 in Q3 2023.
- A 5-year average of $31058.8 and a median of $65000.0 in 2022 frame the typical range for Change in Account Payables.
- The widest YoY moves for Change in Account Payables: up 5375.0% in 2023, down 903.08% in 2023.
- Over 5 years, Change in Account Payables stood at -$4000.0 in 2022, then soared by 5375.0% to $211000.0 in 2023, then tumbled by 147.39% to -$100000.0 in 2024, then increased by 30.0% to -$70000.0 in 2025, then soared by 462.86% to $254000.0 in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered $254000.0, -$70000.0, and $198000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | RenovoRx | 62.20 Mn | 62.20 Mn | 766,000.00 | -206,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -206,000.00 |
| Jun 30, 2026 | -206,000.00 |
| Mar 31, 2026 | 254,000.00 |
| Mar 31, 2026 | 254,000.00 |
| Dec 31, 2025 | -70,000.00 |
| Dec 31, 2025 | -70,000.00 |
| Sep 30, 2025 | 198,000.00 |
| Sep 30, 2025 | 198,000.00 |
| Jun 30, 2025 | -296,000.00 |
| Jun 30, 2025 | -296,000.00 |
| Mar 31, 2025 | 381,000.00 |
| Mar 31, 2025 | 381,000.00 |
| Dec 31, 2024 | -100,000.00 |
| Dec 31, 2024 | -100,000.00 |
| Sep 30, 2024 | 248,000.00 |
| Sep 30, 2024 | 248,000.00 |
| Jun 30, 2024 | 83,000.00 |
| Jun 30, 2024 | 83,000.00 |
| Mar 31, 2024 | -206,000.00 |
| Mar 31, 2024 | -206,000.00 |